Abstract
About 350 million people worldwide have type 2 diabetes (T2D). The major risk factor of T2D is impaired glucose tolerance (pre-diabetes) with 10 % of pre-diabetes subjects develop T2D every year. Understanding of mechanisms of development of T2D from pre-diabetes is important for prevention and treatment of T2D. Chronic stress and chronic low-grade inflammation are prominent risk factors for T2D development in pre-diabetic subjects. However, molecular mechanisms mediating effect of stress and inflammation on development of T2D from pre-diabetes remain unknown. One of such mechanisms might involve kynurenine (KYN) pathway (KP) of tryptophan (TRP) metabolism. We suggested that chronic stress- or chronic low-grade inflammation-induced upregulation of formation of upstream KTP metabolites, KYN and 3-hydroxyKYN, combined with chronic stress- or chronic low-grade inflammation-induced deficiency of pyridoxal 5′-phosphate, a co-factor of downstream enzymes of KTP, triggers overproduction of diabetogenic downstream KYN metabolites, kynurenic acid (KYNA) and 3-hydroxyKYNA (also known as xanthurenic acid (XA)). As the initial assessment of our working hypothesis, we evaluated plasma levels of up- and downstream KP metabolites in the same samples of T2D patients. KYN, XA, and KYNA levels in plasma samples of T2D patients were higher than in samples of non-diabetic subjects. Our results provide further support of “kynurenine hypothesis of insulin resistance and its progression to T2D” that suggested that overproduction of diabetogenic KP metabolites, induced by chronic stress or chronic low-grade inflammation, is one of the mechanisms promoting development of T2D from pre-diabetes. Downstream metabolites of KP might serve as biomarkers of T2D and targets for clinical intervention.
Similar content being viewed by others
Abbreviations
- T2D:
-
Type 2 diabetes
- IR:
-
Insulin resistance
- TRP:
-
Tryptophan
- NAD:
-
Nicotinamide adenine dinucleotide
- IFNG:
-
Interferon gamma
- LPS:
-
Lipopolysaccharide
- KP:
-
Kynurenine pathway of TRP metabolism
- KYN:
-
Kynurenine
- KYNA:
-
Kynurenic acid
- 3-HKYN:
-
3-hydroxykynurenine
- 3-HKYNA:
-
3-hydroxykynurenic acid
- XA:
-
Xanthurenic acid
- 3-HAA:
-
3-hydroxyanthranilic acid
- KMO:
-
Kynurenine 3-monooxygenase
- P5P:
-
Pyridoxal 5′-phosphate
- KAT:
-
Kynurenine aminotransferase
- KYNase:
-
Kynureninase
- IDO:
-
Indoleamine-2,3-dioxygenase
- TDO:
-
Tryptophan-2,3-dioxygenase
- HIV:
-
Human immunodeficiency virus
- HCV:
-
Hepatitis C virus
- HOMA:
-
Homeostatic model assessment
References
Hackett RA, Steptoe A, Kumari M (2014) Association of diurnal patterns in salivary cortisol with type 2 diabetes in the Whitehall II study. J Clin Endocrinol Metab 99:4625–4631. doi:10.1210/jc.2014-2459
Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219–246
Connick JH, Stone TW (1985) The role of kynurenines in diabetes mellitus. Med Hypotheses 18:371–376
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–477
Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM (1996) Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem 66:996–1004
Musajo L (1935) L’acido xanthurenico. Rend Accad Nazl Lincci 21:368–371
Mahuren JD, Dubeski PL, Cook NJ, Schaefer AL, Coburn SP (1999) Adrenocorticotropic hormone increases hydrolysis of B-6 vitamers in swine adrenal glands. J Nutr 129:1905–1908
Paul L, Ueland PM, Selhub J (2013) Mechanistic perspective on the relationship between pyridoxal 5′-phosphate and inflammation. Nutr Rev 71:239–244
Rios-Avila L, Nijhout HF, Reed MC, Sitren HS, Gregory JF 3rd (2013) A mathematical model of tryptophan metabolism via the kynurenine pathway provides insights into the effects of vitamin B-6 deficiency, tryptophan loading, and induction of tryptophan 2,3-dioxygenase on tryptophan metabolites. J Nutr 143:1509–1519. doi:10.3945/jn.113.174599
Kotake Y (1955) Xanthurenic acid, an abnormal metabolite of tryptophan and the diabetic symptoms caused in albino rats by its production. J Vitaminol (Kyoto) 1:73–87
Ikeda S, Kotake Y (1984) Urinary excretion of xanthurenic acid and zinc in diabetes: 1) separation of xanthurenic acid-Zn2+ complex by ion-exchange chromatography. Acta Vitaminol Enzymol 6:23–28
Okamoto H (1981) Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin-dependent diabetes. Mol Cell Biochem 37:43–61
Murakami E, Kotake Y (1972) Studies on the xanthurenic acid-insulin complex. 3. Distribution of xanthurenic acid and formation of xanthurenic acid-insulin complex in serum. J Biochem 72:251–259
Meyramov G, Korchin V, Kocheryzkina N (1998) Diabetogenic activity of xanturenic acid determined by its chelating properties? Transplant Proc 30:2682–2684
Oxenkrug G (2013) Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol 48:294–301. doi:10.1007/s12035-013-8497-4
Oxenkrug GF, Turski WA, Zgrajka W, Weinstock JV, Summergrad P (2013) Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients. Hepat Res Treat 2013: 149247
Manusadzhian VG, Kniazev IA, Vakhrusheva LL (1974) Mass spectrometric identification of xanthurenic acid in pre-diabetes. Vopr Med Khim 20:95–97
Midttun O, Ulvik A, Pedersen E, Ebbing M, Bleie O et al (2011) Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 141:611–617
Marchetti P, Masiello P, Benzi L, Cecchetti P, Fierabracci V, Giannarelli R, Gregorio F, Brunetti P et al (1989) Effects of metformin therapy on plasma amino acid pattern in patients with maturity-onset diabetes. Drugs Exp Clin Res 15:565–570
Do MT, Kim HG, Tran TT, Khanal T, Choi JH, Chung YC, Jeong TC, Jeong HG (2014) Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Toxicol Appl Pharmacol 280:138–148. doi:10.1016/j.taap.2014.07.021
Khattab M, Abul-Fadl M, Khalafallah A, Hamza S (1972) Studies on the urinary excretion of certain tryptophan metabolites in diabetics. J Egypt Med Assoc 55:531–541
Calandra P (1977) Identification of tryptophan metabolites in the healthy epidermis of diabetics. Acta Diabetol Lat 14:1426-37
Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR (2011) Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem 117:254–258. doi:10.3109/13813455.2011.623705
Hayaishi O (1976) Properties and function of indoleamine 2,3-dioxygenase. J Biochem 79:13–21
Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G (2010) Neopterin, a prognostic marker in human malignancies. Cancer Lett 287:13–22
Oxenkrug G, Tucker KL, Requintina P, Summergrad P (2011) Neopterin, a marker of interferon-gamma-inducible inflammation, correlates with pyridoxal-5′-phosphate, waist circumference, HDL-cholesterol, insulin resistance and mortality risk in adult Boston community dwellers of Puerto Rican origin. Am J Neuroprot Neuroregen 3:48–52
Shibata K, Mushiage M, Kondo T, Hayakawa T, Tsuge H (1955) Effects of vitamin B6 deficiency on the conversion ratio of tryptophan to niacin. Biosci Biotechnol Biochem 59:2060–2063
Yeh JK, Brown RR (1977) Effects of vitamin B-6 deficiency and tryptophan loading on urinary excretion of tryptophan metabolites in mammals. J Nutr 107:261–271
Bender DA, Njagi EN, Danielian PS (1990) Tryptophan metabolism in vitamin B6-deficient mice. Br J Nutr 63:27–36
Midttun O, Ulvik A, Ringdal Pedersen E, Ebbing M, Bleie O, Schartum-Hansen H, Nilsen RM, Nygard O et al (2011) Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 141:611–617
Pedersen ER, Tuseth N, Eussen SJ, Ueland PM, Strand E, Svingen GF, Midttun Ø, Meyer K et al (2015) Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 35:455–462. doi:10.1161/ATVBAHA.114.304674
Oxenkrug G, Ratner R, Summergrad P (2013) Kynurenines and vitamin B6: link between diabetes and depression. J Bioinformatics Diabetes 1:1–9. doi:10.14302/issn.2374-9431.jbd-13-212
Oxenkrug G (2015) 3-Hydroxykynurenic acid and type 2 diabetes: implications for aging, obesity, depression, Parkinson’s disease and schizophrenia. In: Engin A, Engin AB (eds) Tryptophan metabolism: implications for biological processes, health and diseases, molecular and integrative toxicology. Springer International Publishing, Switzerland, pp 173–195. doi:10.1007/978-3-319-15630-9_8
Polyzos KA, Ketelhuth DF (2015) The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease. An emerging field. Hamostaseologie 35:128–136. doi:10.5482/HAMO-14-10-00562
Acknowledgments
This study is supported by NIMH104810. The author highly appreciates BioreclamationIVT, NY, USA, for providing plasma samples and Marieke van der Hart, PhD, for the excellent help with biochemical analyses
Conflict of Interest
The author declares that he has no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oxenkrug, G.F. Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. Mol Neurobiol 52, 805–810 (2015). https://doi.org/10.1007/s12035-015-9232-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-015-9232-0